Gapping up
In reaction to strong earnings/guidance: NXTD +17.6%, MOBL +14.1%
M&A news:
In reaction to strong earnings/guidance: NXTD +17.6%, MOBL +14.1%
M&A news:
- EGAS +69.1% (agrees to be acquired by First Reserve for $13.10/share in cash)
- AYA +2.7% (confirms discussions with William Hill PLC are ongoing),
- SU +0.9% (mulling a potential sale of its of its Petro-Canada retail gasoline station unit, according to Reuters)
Select metals/mining stocks trading higher: DRD +2.9%, PAAS +2.5%, AG +2.4%, AUY +2.2%, MT +1.9%, ABX +1.3%,SLV +0.8%
Other news:
Other news:
- IPCI +15.5% (receives FDA tentative approval for generic Seroquel XR)
- TSRO +15% (present successful Niraparib Phase 3 results of ENGOT-OV16/NOVA trial)
- MYL +11.6% (agrees to settlement on Medicaid rebate classification for EpiPen Auto-Injector, lowers FY16 EPS guidance; also upgraded to Strong Buy from Market Perform at Raymond James)
- MZOR +7.4% (Mazor Robotics receives first pre-launch orders for Mazor X System)
- CLDX +6% (reports Phase 2 Study of Glembatumumab Vedotin met primary overall response endpoint)
- EXEL +4.9% (Exelixis and Ipsen (IPSEY) report Phase 2 study of Cabozantinib met the primary endpoint of improving progression-free survival)
- CASC +4% (presentation of tucatinib in combination therapy in patients with cutaneous HER2+ metastatic breast cancer)
- LPCN +3.5% (cont strength after Friday's announcement of U.S. District Court in Delaware granted its motion to dismiss a lawsuit filed by Clarus Therapeutics)
- MRK +3.3% (announced findings from the final overall survival analysis from the KEYNOTE-002 study)
- CRM +2.9% (reports that co is no longer interesting in offer for TWTR)
- TSLA +2.2% (Elon Musk in series of tweets teases October 17 product unveiling, says it and SolarCity (SCTY) won't need to raise debt or equity in Q4)
- IONS +2.1% (Biogen (BIIB) and Ionis Pharmaceuticals (IONS) presented new data from the clinical program for nusinersen)
- VRX +2% (in sympathy with MYL)
- TEVA +1.9% (in sympathy with MYL)
- PRGO +1.4% (in sympathy with MYL)
Analyst comments:
- UA +2.5% (upgraded to Outperform from Market Perform at Wells Fargo )
- ATHN +2% (upgraded to Buy from Hold at Evercore ISI)
- DE +1.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- TSN +1.2% (upgraded to Buy from Outperform at CLSA)
- STO +0.8% (added to European Focus List at Citigroup)